Regulation
FDA selects Cadence’s HypertensionOS as second TEMPO pilot participant
The FDA has selected Cadence's HypertensionOS software as the second participant in its TEMPO (Total Product Life Cycle Advisory for Digital Health Devices) Pilot program. TEMPO provides premarket guidance and accelerated pathways for digital health devices, signaling regulatory momentum for software-based cardiovascular management tools.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network